RSV vaccine safety for lung and stem cell transplant patients
This trial tests two RSV vaccine schedules in people who have had a lung transplant or a stem cell transplant. It looks at whether the vaccines are safe and how well they boost the immune system against RSV, a common respiratory virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a lung transplant at least 3 months ago or a stem cell transplant between 3 months and 5 years ago.
- You are 18 years or older.
- You have not had an RSV vaccine before.
- You do not have active cancer (except certain skin cancers).
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
This trial studies how well the RSV vaccine works in people who have had a stem cell transplant or CAR-T therapy for a blood cancer. It aims to see if the vaccine can protect you from RSV, a common respiratory virus that can be serious for people with weakened immune systems.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Hear when a new Immunocompromised Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.